Brain-Derived Neurotrophic Factor in Patients with Huntington's Disease
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Reduced Brain-Derived Neurotrophic Factor (BDNF) levels have been described in a number of patho-physiological conditions, most notably, in Huntington's disease (HD), a progressive neurodegenerative disorder. Since BDNF is also produced in blood, we have undertaken the measurement of its peripheral levels in the attempt to identify a possible link with HD prognosis and/or its progression. Here we evaluated BDNF level in 398 blood samples including 138 controls, 56 preHD, and 204 HD subjects. We found that BDNF protein levels were not reliably different between groups, whether measured in plasma (52 controls, 26 preHD, 105 HD) or serum (39 controls, 5 preHD, 29 HD). Our experience, and a re-analysis of the literature highlighted that intra-group variability and methodological aspects affect this measurement, especially in serum. We also assessed BDNF mRNA levels in blood samples from 47 controls, 25 preHD, and 70 HD subjects, and found no differences among the groups. We concluded that levels of BDNF in human blood were not informative (mRNA levels or plasma protein level) nor reliable (serum protein levels) as HD biomarkers. We also wish to warn the scientific community in interpreting the significance of changes measured in BDNF protein levels in serum from patients suffering from different conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 mRNA levels of other HD-related genes in control and HD patients. Samples are from Italian Cohort C. Blood mRNA levels of (A) ANXA1 and (B) ROCK1 were measured with two different normalisation strategies (ß-actin mRNA levels (ß-ACT), according to [25], and EAR levels, according to [24].](https://figures.cochat.ai/paper-figures/0e1f7bacf29a461f9f513e18e813b527/brain-derived-neurotrophic-factor-in-patients-with-huntington-s-disease-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Key biomarkers include polyQ-Htt and Tau, which are detected in the CSF, as well as BDNF, which is measurable in the blood [253,254,255,256].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [256]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease
Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., MacDonald, M. E., Friedlander, R. M., Silani, V., Hayden, M. R., et al. (2001) · Science · doi:10.1126/science.1059581 · Cited by 1,123 · cited 1×
“This is not due to the ELISA assay itself that has been extensively validated in cells, brain tissue and plasma samples [22,23,32].”
BackgroundSelf-citationBrain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947 · cited 4×
“We previously demonstrated that transcription from the BDNF promoters II, IV, and VI was reduced in the brains of HD animal models and in human postmortem brain tissue [10].”
BackgroundInfluentialSelf-citationThe impact of age, weight and gender on BDNF levels in human platelets and plasma
Lommatzsch, M., Zingler, D., Schuhbaeck, K., Schloetcke, K., Zingler, C., Schuff-Werner, P., & Virchow, J. C. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.002 · Cited by 842 · cited 3×
“, (2005) have shown that different types of blood collection tubes (EDTA or heparin-treated) can influence the BDNF content detected in plasma [17].”
BackgroundLangbehn, D., Brinkman, R., Falush, D., Paulsen, J., Hayden, M., & on behalf of an International Huntington's Disease Collaborative Group (2004) · Clinical Genetics · doi:10.1111/j.1399-0004.2004.00241.x · Cited by 817 · cited 2×
“For each pre-HD individual, the estimated probability of onset within the next 5 years was calculated on the basis of the number of CAG repeats and his/her present age, according to Langbehn [19].”
MethodIndividuality and variation in gene expression patterns in human blood
Whitney, A. R., Diehn, M., Popper, S. J., Alizadeh, A. A., Boldrick, J. C., Relman, D. A., & Brown, P. O. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252784499 · Cited by 778 · cited 1×
“Furthermore, microarray studies on blood samples from healthy subjects have shown intra-individual variation in the expression of several genes due to differences in the relative proportions of specific blood cell subsets, gender, age, and the time of day at which the blood was sampled [34].”
BackgroundBrain-derived Neurotrophic Factor Is Stored in Human Platelets and Released by Agonist Stimulation
Fujimura, H., Chen, R., Nakamura, T., Nakahashi, T., Kambayashi, J.-I., Sun, B., Altar, C., & Tandon, N. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613072 · Cited by 777
Blood BDNF Concentrations Reflect Brain-Tissue BDNF Levels across Species
Klein, A. B., Williamson, R., Santini, M. A., Clemmensen, C., Ettrup, A., Rios, M., Knudsen, G. M., & Aznar, S. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000738 · Cited by 726 · cited 1×
“BDNF has been detected also in the blood [6,7,8].”
BackgroundPruunsild, P., Kazantseva, A., Aid, T., Palm, K., & Timmusk, T. (2007) · Genomics · doi:10.1016/j.ygeno.2007.05.004 · Cited by 699 · cited 1×
“The human BDNF gene is characterised by very complex regulation as it contains nine different promoters that act independently to modulate the transcription of BDNF mRNA in a stimulus- and time- specific manner [33].”
Background
Cited by
Items 101–140 of 140
Nisaa, A. A., Mageswary, M. U., Pei, X., Kadir, M. N., Oon, C. E., Rajendran, D., Tan, J. J., Roslan, F. F., Balasubramaniam, S. D., Sany, S. B., et al. (2025) · Beneficial Microbes · doi:10.1163/18762891-bja00061 · Cited by 8
Sabaghi, A., Heirani, A., mahmodi, H., & Sabaghi, S. (2019) · Sport Sciences for Health · doi:10.1007/s11332-019-00586-6 · Cited by 9
Xu, P., Mageswary, M. U., Nisaa, A. A., Balasubramaniam, S. D., Samsudin, S. B., Rusdi, N. I. B. M., Jerip, A. R., Oon, C. E., Bakar, M. H. A., Rajendran, D., et al. (2025) · Beneficial Microbes · doi:10.1163/18762891-bja00079 · Cited by 8
Rehabilitation training in neural restitution
Clinch, S. P., Busse, M. E., Döbrössy, M. D., & Dunnett, S. B. (2017) · Progress in brain research · doi:10.1016/bs.pbr.2016.12.006 · Cited by 7
Brain-Derived Neurotrophic Factor and Stem Cell-Based Technologies in Huntington’s Disease Therapy
Kerkis, I., da Silva, J. M., Wenceslau, C. V., Mambelli-Lisboa, N. C., & Frare, E. O. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91226 · Cited by 8
“Expression of BDNF is reduced among patients with Alzheimer’s [22, 23] and Huntington’s disease [7, 24].”
BackgroundTherapeutic Potential of AAV1-Rheb(S16H) Transduction against Neurodegenerative Diseases
Nam, Y., Moon, G. J., & Kim, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063064 · Cited by 7
Chiperi, L. E., Huţanu, A., Tecar, C., & Muntean, I. (2023) · Clinics and Practice · doi:10.3390/clinpract13050113 · Cited by 6
Neurodegenerative Diseases - Molecular Mechanisms and Current Therapeutic Approaches
Tunalı, N. E. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.83153 · Cited by 10
Nucleic Acid-Based Strategies to Treat Neurodegenerative Diseases
Panda, S., Chatterjee, O., & Chatterjee, S. (2023) · Springer eBooks · doi:10.1007/978-981-19-8520-1_4 · Cited by 6
Mesenchymal Stromal Cell Secretome for Tissue Repair
Gnecchi, M., Ciuffreda, M. C., & Mura, M. (2020) · Springer eBooks · doi:10.1007/978-3-319-08831-0_43 · Cited by 6
Wanas, H., Rabie, M. A., Aboulhoda, B. E., Ramadan, N. M., Abdel-Wahab, S. E. A., Abdallah, S. S. K., Ali, E. N., Khayruddeen, L. N., Elhassan, Y. H., Alghabban, H. M., et al. (2024) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00724-z · Cited by 4
Ramachandran, S., & Sumathi, T. (2025) · NeuroToxicology · doi:10.1016/j.neuro.2025.04.005 · Cited by 3
Serum biomarkers in normal pressure hydrocephalus
Mehmedika-Suljić, E., Izetbegović, S., Serdarević, N., Rovčanin, B., Mahmutbegović, N., Mehičević, A., & Omerhodžić, I. (2023) · Medicinski Glasnik · doi:10.17392/1590-23 · Cited by 3
Huntington’s Disease: Molecular Pathogenesis and New Therapeutic Perspectives
Perandones, C., & Muñoz-Sanjuán, I. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6455-5_6 · Cited by 3
“The effect of BDNF signaling on synaptic plasticity and axonal transport in MSNs refl ects a critical role for this pathway in HD pathophysiology [ 88 , 139 – 159 ].”
BackgroundLoe, M. L., Indharty, R. S., Siahaan, A. M. P., Tandean, S., & Riawan, W. (2020) · Sains Malaysiana · doi:10.17576/jsm-2020-4902-15 · Cited by 3
Linking Huntington disease, brain-derived neurotrophic factor, and depressive-like behaviors
Plácido, E., Nascimento-Castro, C. D. P., Welter, P. G., Gil‐Mohapel, J., & Brocardo, P. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817935-2.00042-8 · Cited by 4
Biomarkers in Huntington’s Disease
Killoran, A. (2021) · Neuromethods · doi:10.1007/978-1-0716-1712-0_10 · Cited by 3
Danna, R., Kondle, S., Amar, O., Mabourakh, M., Chen, G., Fadol, W. B., & Mohieldin, A. M. (2025) · Biology · doi:10.3390/biology14121787 · Cited by 2
“Key biomarkers include polyQ-Htt and Tau, which are detected in the CSF, as well as BDNF, which is measurable in the blood [253–256].”
Silva, N. K. D. G. T., Costa, G. D. A., de Almeida, M. G., Marianno, P., Belo-Silva, A. E., da Rovare, V. P., Rae, M. B., Eichler, R. A. D. S., Chivers, P., Bailey, A., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110733 · Cited by 3
Pour, H. V., Motamedi, S., Mirzaei, B., Fernandes, C. B. L., & Mourtaja, H. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151572 · Cited by 2
Mesenchymal Stromal Cell Secretome for Tissue Repair
Gnecchi, M., Ciuffreda, M. C., & Mura, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-37076-7_43-1 · Cited by 3
Park, K. W., Joo, J. Y., & Kim, S. T. (2022) · European Journal of Ophthalmology · doi:10.1177/11206721221099488 · Cited by 1
“BDNF has been mainly studied in patients with neurological disorders, such as epilepsy, Alzheimer’s disease (AD), and Huntington’s disease.(9,10) The anatomy and function of the eye are similar to those of the brain.”
BackgroundSaliva as a Relevant Biofluid for Huntington’s Disease Biomarker Research
Granger, S. W., & Thomas, E. A. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-32815-2_4 · Cited by 1
BDNF-AS as a promising downregulated biomarker for multiple sclerosis pathogenesis and diagnosis
Kamal, A., Swellam, M. M., Shalaby, N., Darwish, M. K., & El-Nahrery, E. M. A. (2025) · INNOSC Theranostics and Pharmacological Sciences · doi:10.36922/itps.4407 · Cited by 1
Peripheral brain-derived neurotrophic factor in stable love relationships: a study in healthy humans
Marazziti, D., Mucci, F., Gurrieri, R., Palego, L., Betti, L., Giannaccini, G., & Carter, C. S. (2026) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2026.2624464 · Cited by 1
“Also, it is worth highlighting some pre-clinical methodological limitations: the accurate measurement of peripheral BDNF levels is challenging (Zuccato et al. 2011).”
Jacques, C. E. D., Guerreiro, G., Lopes, F. F., de Souza, C. F. M., Giugliani, R., & Vargas, C. R. (2023) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-023-01149-w · Cited by 1
Monitoring transcriptomic responses of SH-SY5Y cells to amyloid treatments
Jain, A. K. (2013) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/9ayp-rx02
Gutierrez, A. M. (2018) · eScholarship (California Digital Library)
Induced pluripotent stem cells as a potential treatment for Huntington’s disease
Srinageshwar, B., Dunbar, G. L., & Rossignol, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822229-4.00002-4
(2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.146
Malattia di Huntington: aspetti diagnostici attuali e applicazioni pratiche
Youssov, K., & Bachoud‐Lévi, A. (2018) · EMC - Neurologia · doi:10.1016/s1634-7072(18)89403-x
Self-citationFluid and Imaging Markers of Huntington’s Disease
Farag, M., Scahill, R. I., Wild, E. J., & Tabrizi, S. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_11
Self-citationSandrini, L. (2019) · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) · doi:10.13130/sandrini-leonardo_phd2019-12-11
Buist, M. (2021) · Mspace (University of Manitoba)
Koley, R., De, S., Ghosh, A., Bhattacharjee, D., Mitra, A., Mondal, B., Pahari, A., Nandi, M., Kanri, R., Dasgupta, S., et al. (2026) · In vitro models · doi:10.1007/s44164-026-00111-3
Rakotoarisoa, M. (2021) · theses.fr (ABES) · doi:10.70675/7bf6365czfebbz4b3az9400z0a82f6d9364f
Brain-derived neurotrophic factor electrochemical biosensors: A review
Kayal, A., & Howlader, M. M. R. (2026) · Next research. · doi:10.1016/j.nexres.2026.101778
Turčić, M., & Vurušić, K. (2026) · Galician Medical Journal · doi:10.21802/e-gmj2026-a24
Metadata
- Authors
- Zuccato, C., Marullo, M., Vitali, B., Tarditi, A., Mariotti, C., Valenza, M., Lahiri, N., Wild, E. J., Sassone, J., Ciammola, A., Bachoud-Lèvi, A. C., Tabrizi, S. J., Di Donato, S., & Cattaneo, E.
- Affiliations
- University of Milan (IT)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- National Hospital for Neurology and Neurosurgery (GB)
- IRCCS Istituto Auxologico Italiano (IT)
- Corresponding author
- Cattaneo, Elena
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-08-12
- Volume
- 6
- Issue
- 8
- Pages
- e22966
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3155522
- OpenAlex
- W2053424572
- Cited by
- 138
- References
- 35
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 3 · 2023: 10 · 2022: 7 · 2021: 16 · 2020: 17 · 2019: 10 · 2018: 11 · 2017: 9 · 2016: 6 · 2015: 8 · 2014: 10 · 2013: 11 · 2012: 5
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- CHDI Foundation
- National Institute for Health and Care Research (CL-2009-18-005)
- European Commission
- University College London Hospitals NHS Foundation Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- brain-derived neurotrophic factor, Huntington's disease, serum BDNF, plasma BDNF levels, neurodegeneration, measurement variability, disease progression
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antidepressive Agents, Tricyclic, Benzodiazepines, Enzyme-Linked Immunosorbent Assay, Female, France, Humans, Huntington Disease, Italy, London, Male, Middle Aged, RNA, Messenger, Antipsychotic Agents, Neurotransmitter Uptake Inhibitors, Cohort Studies, Gene Expression, Annexins, Brain-Derived Neurotrophic Factor, Reverse Transcriptase Polymerase Chain Reaction, rho-Associated Kinases, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.